Evidence map›Paper›PMID 26558387›Full record

ArticlePloS one2015

PCR-Based Simple Subgrouping Is Validated for Classification of Gliomas and Defines Negative Prognostic Copy Number Aberrations in IDH Mutant Gliomas.

Shunsuke Nakae, Hikaru Sasaki, Saeko Hayashi, Natsuki Hattori, Masanobu Kumon, Yuya Nishiyama, Kazuhide Adachi, Shinya Nagahisa, Takuro Hayashi, Joji Inamasu and 3 more

Abstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Consequences ofMolecules (Basel, Switzerland) · 2019
    Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Shunsuke NakaeDepartment of Neurosurgery, Fujita Health University, Toyoake, Aichi, Japan.
Hikaru SasakiDepartment of Neurosurgery, Keio University, Tokyo, Japan.
Saeko HayashiDepartment of Neurosurgery, Keio University, Tokyo, Japan.
Natsuki HattoriDepartment of Neurosurgery, Fujita Health University, Toyoake, Aichi, Japan.
Masanobu KumonDepartment of Neurosurgery, Fujita Health University, Toyoake, Aichi, Japan.
Yuya NishiyamaDepartment of Neurosurgery, Fujita Health University, Toyoake, Aichi, Japan.
Kazuhide AdachiDepartment of Neurosurgery, Fujita Health University, Toyoake, Aichi, Japan.
Shinya NagahisaDepartment of Neurosurgery, Fujita Health University, Toyoake, Aichi, Japan.
Takuro HayashiDepartment of Neurosurgery, Fujita Health University, Toyoake, Aichi, Japan.
Joji InamasuDepartment of Neurosurgery, Fujita Health University, Toyoake, Aichi, Japan.
Masato AbeDepartment of Pathology, Fujita Health University, Toyoake, Aichi, Japan.
Mitsuhiro HasegawaDepartment of Neurosurgery, Fujita Health University, Toyoake, Aichi, Japan.
Yuichi HiroseDepartment of Neurosurgery, Fujita Health University, Toyoake, Aichi, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Genetic subgrouping of gliomas has been emphasized recently, particularly after the finding of isocitrate dehydrogenase 1 (IDH1) mutations. In a previous study, we investigated whole-chromosome copy number aberrations (CNAs) of gliomas and have described genetic subgrouping based on CNAs and IDH1 mutations. Subsequently, we classified gliomas using simple polymerase chain reaction (PCR)-based methods to improve the availability of genetic subgrouping. We selected IDH1/2 and TP53 as markers and analyzed 237 adult supratentorial gliomas using Sanger sequencing. Using these markers, we classified gliomas into three subgroups that were strongly associated with patient prognoses. These included IDH mutant gliomas without TP53 mutations, IDH mutant gliomas with TP53 mutations, and IDH wild-type gliomas. IDH mutant gliomas without TP53 mutations, which mostly corresponded to gliomas carrying 1p19q co-deletions, showed lower recurrence rates than the other 2 groups. In the other high-recurrence groups, the median progression-free survival (PFS) and overall survival (OS) of patients with IDH mutant gliomas with TP53 mutations were significantly longer than those of patients with IDH wild-type gliomas. Notably, most IDH mutant gliomas with TP53 mutations had at least one of the CNAs +7q, +8q, -9p, and -11p. Moreover, IDH mutant gliomas with at least one of these CNAs had a significantly worse prognosis than did other IDH mutant gliomas. PCR-based mutation analyses of IDH and TP53 were sufficient for simple genetic diagnosis of glioma that were strongly associated with prognosis of patients and enabled us to detect negative CNAs in IDH mutant gliomas.

Indexed as

Chromosome AberrationsAdultBrain NeoplasmsDisease-Free SurvivalDNA Mutational AnalysisExonsFemaleGliomaHumansIsocitrate DehydrogenaseKaplan-Meier EstimateMaleMiddle AgedMutationNeoplasm GradingNeoplasm Recurrence, LocalIDH1 protein, humanIDH2 protein, humanIsocitrate DehydrogenaseTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID26558387
PMCPMC4641694

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.